ARA-290 (cibinetide): what is the nerve-pain research about?

Why are people interested in it?

Burning, tingling or numbness can lead someone to search for “nerve repair”. Peripheral neuropathy means a problem affecting nerves outside the brain and spinal cord; it has many possible causes and symptoms. Small nerve fibres help carry pain and temperature signals and contribute to some automatic body functions. A symptom alone cannot identify the cause. For an individual problem, a healthcare professional can assess the symptoms and possible causes. For the broader question, see what neuropathy means and how it is assessed.1

What is the idea behind the peptide?

Researchers designed ARA-290 using the structure of erythropoietin, a natural hormone involved in red-blood-cell production. They investigated whether the peptide could influence a proposed tissue-protection pathway without the same blood-cell stimulating effect. This is a research idea, not proof that the peptide reverses nerve injury in people or that it can replace erythropoietin medicines.64

What have people actually been studied for?

Small controlled trials involved people with sarcoidosis—a condition associated with inflammation in different organs—and painful small-fibre symptoms; another trial involved people with type 2 diabetes and painful extremities. The studies used questionnaires and, in some cases, images of fine nerve fibres in the cornea, the clear surface of the eye. A measurement at one site is not the same as a proven return of feeling or function throughout the body. Read what each human study measured.246

Does a designation mean it is approved?

The European Medicines Agency records a 2013 orphan designation for cibinetide for sarcoidosis. Orphan designation encourages development for a rare condition; it is not marketing authorisation and does not establish that a product has passed an approval review. The record’s description of development is historical. Check the relevant current regulator and exact product rather than assuming the same status in every country.7

What is known about safety?

The studies were small and short. In one 64-person sarcoidosis trial, the EU results registry recorded serious events in three participants receiving cibinetide and none receiving placebo among those included in its safety report; one event was assessed as related. Two active treatment allocations could not be verified. The small numbers do not establish a reliable rate or whether every event was caused by the peptide. Longer-term effects and the quality of an unrelated product are not established.

A 2017 protocol for a separate eye study reports that an earlier development safety update recorded one serious event involving suicidal thoughts in another cibinetide study; the relationship to the study drug was assessed as possible. The protocol does not establish that cibinetide caused the event or how often it might occur, and we have not independently reviewed the original safety report.58

How does this connect to other “nerve support” claims?

Different causes require different questions. For example, excess vitamin B6 from supplements can itself affect nerves; that is not evidence that every symptom is caused by B6. See vitamin B6 and nerve safety. ARA-290 and BPC-157 are different peptides: the BPC-157 human-evidence guide explains why a repair claim needs its own studies. Neither page gives a treatment plan.1